Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NDRA Stock Summary
Top 10 Correlated ETFs
NDRA
In the News

ENDRA Life Sciences Inc. (NDRA) Q3 2023 Earnings Call Transcript
ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Francois Michelon - Chairman and Chief Executive Officer Michael Thornton - Chief Technology Officer Irina Pestrikova - Senior Director, Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Third Quarter 2023 Financial Results Conference Call. All participants will be in a listen-only mode.

ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three and nine months ended September 30, 2023 on Tuesday, November 14, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate d.

ENDRA Life Sciences Inc. (NDRA) Q2 2023 Earnings Call Transcript
ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Francois Michelon - Chairman and Chief Executive Officer Michael Thornton - Chief Technology Officer Irina Pestrikova - Senior Director, Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Second Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.

ENDRA Life Sciences Inc. (NDRA) Q1 2023 Earnings Call Transcript
ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Francois Michelon - Chairman & Chief Executive Officer Michael Thornton - Chief Technology Officer Irina Pestrikova - Senior Director of Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Inc. First Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.

Why Is ENDRA Life Sciences (NDRA) Stock Down 16% Today?
ENDRA Life Sciences (NASDAQ: NDRA ) stock is sliding lower on Friday after revealing details of its public offering. ENDRA Life Sciences is offering up 862,500 shares of NDRA stock alongside 431,250 warrants to purchase more shares.

ENDRA Life Sciences Inc. (NDRA) Q4 2022 Earnings Call Transcript
ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q4 2022 Earnings Conference Call March 14, 2023 4:30 PM ET Company Participants Yvonne Briggs – LHA Investor Relations Francois Michelon – Chairman and Chief Executive Officer Michael Thornton – Chief Technology Officer Irina Pestrikova – Senior Director-Finance Conference Call Participants Vernon Bernardino – H.C. Wainwright & Company Edward Woo – Ascendiant Capital Operator Good afternoon, and welcome to the ENDRA Life Sciences Incorporated Fourth Quarter 2022 Financial Results Conference Call.

ENDRA Life Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 14, 2023
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months and year ended December 31, 2022 on Tuesday, March 14, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m.

ENDRA Life Sciences Inc. (NDRA) Q3 2022 Earnings Call Transcript
ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Yvonne Briggs - Investor Relations Francois Michelon - Chairman & Chief Executive Officer Michael Thornton - Chief Technology Officer Renaud Maloberti - Chief Commercial Officer Irina Pestrikova - Senior Director of Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Third Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode.

ENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q2 2022 Results - Earnings Call Transcript
ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Yvonne Briggs - IR Francois Michelon - Chairman and CEO Mike Thornton - Chief Technology Officer Renaud Maloberti - CCO Irina Pestrikova - Senior Director, Finance Conference Call Participants Edward Woo - Ascendiant Capital Vernon Bernardino - H.C. Wainwright Operator Good day everyone, and welcome to the ENDRA Life Sciences' Second Quarter 2022 Financial Results Conference Call.

Which Penny Stocks Are Investors Buying Right Now? 3 to Watch
Why investors are buying these penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
NDRA Financial details
NDRA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.03 | 0 | 0 | 0 | 0 | |
Net income per share | -43.49 | -41.48 | -12.47 | -5.47 | -4.57 | |
Operating cash flow per share | -34.2 | -22.9 | -11.22 | -5.44 | -4.42 | |
Free cash flow per share | -34.64 | -23.02 | -11.28 | -5.46 | -4.49 | |
Cash per share | 28.73 | 16.46 | 7.53 | 4.62 | 1.69 | |
Book value per share | 27.74 | 12.7 | 7.47 | 5.27 | 2.49 | |
Tangible book value per share | 27.74 | 12.7 | 7.47 | 5.27 | 2.49 | |
Share holders equity per share | 27.74 | 12.7 | 7.47 | 5.27 | 2.49 | |
Interest debt per share | 0 | 8.17 | 0.96 | 0.33 | 0.2 | |
Market cap | 6.76M | 12.6M | 14.39M | 28.32M | 11.77M | |
Enterprise value | 285.92K | 7.13M | 7.85M | 19.54M | 7.43M | |
P/E ratio | -0.69 | -0.81 | -1.2 | -2.53 | -0.89 | |
Price to sales ratio | 1.09K | 0 | 0 | 0 | 0 | |
POCF ratio | -0.88 | -1.47 | -1.34 | -2.55 | -0.92 | |
PFCF ratio | -0.87 | -1.46 | -1.33 | -2.54 | -0.91 | |
P/B Ratio | 1.08 | 2.65 | 2.01 | 2.63 | 1.63 | |
PTB ratio | 1.08 | 2.65 | 2.01 | 2.63 | 1.63 | |
EV to sales | 46.31 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -0.03 | -0.66 | -0.69 | -1.73 | -0.57 | |
EV to operating cash flow | -0.04 | -0.83 | -0.73 | -1.76 | -0.58 | |
EV to free cash flow | -0.04 | -0.83 | -0.73 | -1.75 | -0.57 | |
Earnings yield | -1.45 | -1.23 | -0.83 | -0.4 | -1.12 | |
Free cash flow yield | -1.15 | -0.69 | -0.75 | -0.39 | -1.1 | |
Debt to equity | 0 | 0.15 | 0.1 | 0.06 | 0.08 | |
Debt to assets | 0 | 0.1 | 0.08 | 0.05 | 0.06 | |
Net debt to EBITDA | 0.77 | 0.5 | 0.58 | 0.78 | 0.34 | |
Current ratio | 7.13 | 3.15 | 8.32 | 7.83 | 5 | |
Interest coverage | 0 | -4.6 | -49.49 | 0 | -611.04 | |
Income quality | 0.79 | 0.65 | 0.92 | 0.99 | 0.97 | |
Dividend Yield | 0 | 0.33 | 0.03 | 0 | 0 | |
Payout ratio | 0 | -0.27 | -0.03 | -0.01 | 0 | |
Sales general and administrative to revenue | 607.8 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 764.9 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.01 | 0 | 0 | 0.02 | |
Capex to revenue | -16.2 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1.46 | -0.38 | -0.31 | -0.2 | -0.86 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 164.76 | 108.85 | 45.79 | 25.47 | 16 | |
ROIC | -1.33 | -2.16 | -1.43 | -0.95 | -1.59 | |
Return on tangible assets | -1.36 | -2.17 | -1.37 | -0.87 | -1.42 | |
Graham Net | 25.02 | 10.41 | 6.48 | 3.92 | 1.43 | |
Working capital | 5.97M | 4.46M | 7.23M | 10.55M | 6.82M | |
Tangible asset value | 6.25M | 4.76M | 7.17M | 10.78M | 7.2M | |
Net current asset value | 5.97M | 4.12M | 6.62M | 10M | 6.46M | |
Invested capital | 0 | 0.15 | 0.1 | 0.06 | 0.08 | |
Average receivables | 76.14K | 131.09K | 253.77K | 195.4K | 0 | |
Average payables | 705.87K | 954.95K | 840.67K | 596.98K | 702.51K | |
Average inventory | 125.56K | 86.44K | 351.53K | 937.1K | 1.96M | |
Days sales outstanding | 8.6K | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.04 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.57 | -3.27 | -1.67 | -1.04 | -1.83 | |
Capex per share | -0.44 | -0.12 | -0.05 | -0.02 | -0.07 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.1 | -1.09M | -0.93 | -0.43 | -0.4 | |
Operating cash flow per share | -1.03 | -1.03M | -0.79 | -0.38 | -0.34 | |
Free cash flow per share | -1.03 | -1.04M | -0.8 | -0.38 | -0.34 | |
Cash per share | 2.54 | 1.63M | 0.74 | 0.8 | 0.43 | |
Book value per share | 3.23 | 2.4M | 1.42 | 1.16 | 0.68 | |
Tangible book value per share | 3.23 | 2.4M | 1.42 | 1.16 | 0.68 | |
Share holders equity per share | 3.23 | 2.4M | 1.42 | 1.16 | 0.68 | |
Interest debt per share | 0.19 | 174.28K | 0.16 | 0.08 | 0.06 | |
Market cap | 19.33M | 12.21 | 7.26M | 8.39M | 8.53M | |
Enterprise value | 11.9M | -4.34M | 5.41M | 4.05M | 5.63M | |
P/E ratio | -1.4 | 0 | -0.62 | -0.82 | -0.69 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -5.95 | 0 | -2.89 | -3.7 | -3.28 | |
PFCF ratio | -5.93 | 0 | -2.86 | -3.7 | -3.28 | |
P/B Ratio | 1.89 | 0 | 1.61 | 1.21 | 1.64 | |
PTB ratio | 1.89 | 0 | 1.61 | 1.21 | 1.64 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -3.54 | 1.34 | -1.89 | -1.39 | -1.84 | |
EV to operating cash flow | -3.66 | 1.41 | -2.16 | -1.78 | -2.17 | |
EV to free cash flow | -3.65 | 1.39 | -2.14 | -1.78 | -2.17 | |
Earnings yield | -0.18 | -267.47K | -0.41 | -0.3 | -0.36 | |
Free cash flow yield | -0.17 | -256.12K | -0.35 | -0.27 | -0.3 | |
Debt to equity | 0.06 | 0.08 | 0.11 | 0.07 | 0.08 | |
Debt to assets | 0.05 | 0.06 | 0.08 | 0.05 | 0.06 | |
Net debt to EBITDA | 2.21 | 1.34 | 0.64 | 1.49 | 0.95 | |
Current ratio | 6.78 | 5 | 3.01 | 3.98 | 2.95 | |
Interest coverage | -148.5 | 139.31 | -859.96 | 0 | 0 | |
Income quality | 0.94 | 0.94 | 0.85 | 0.89 | 0.84 | |
Dividend Yield | 0 | 221.21 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0.01 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.25 | -0.57 | -0.38 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 8.93 | 7.67M | 5.45 | 3.33 | 2.48 | |
ROIC | -0.3 | -0.4 | -0.54 | -0.38 | -0.52 | |
Return on tangible assets | -0.28 | -0.35 | -0.44 | -0.28 | -0.41 | |
Graham Net | 2.28 | 1.38M | 0.49 | 0.65 | 0.3 | |
Working capital | 9.86M | 6.82M | 3.69M | 6.05M | 4.23M | |
Tangible asset value | 10.2M | 7.2M | 4.5M | 6.93M | 5.2M | |
Net current asset value | 9.43M | 6.46M | 3.36M | 5.77M | 3.99M | |
Invested capital | 0.06 | 0.08 | 0.11 | 0.07 | 0.08 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 710.88K | 625.33K | 568.99K | 469.48K | 417.04K | |
Average inventory | 2.5M | 2.64M | 2.69M | 2.75M | 2.76M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.34 | -0.45 | -0.65 | -0.37 | -0.6 | |
Capex per share | 0 | -12.85K | -0.01 | 0 | 0 |
NDRA Frequently Asked Questions
What is ENDRA Life Sciences Inc. stock symbol ?
ENDRA Life Sciences Inc. is a US stock , located in Ann arbor of Mi and trading under the symbol NDRA
What is ENDRA Life Sciences Inc. stock quote today ?
ENDRA Life Sciences Inc. stock price is $1.5 today.
Is ENDRA Life Sciences Inc. stock public?
Yes, ENDRA Life Sciences Inc. is a publicly traded company.